Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Release

Dicerna to Participate in Upcoming Investor Conferences

Aug 29, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 29, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in September.

  • H.C. Wainwright 20th Annual Global Investment Conference, Wednesday, September 5, 2018 at 1:45 p.m. ET, at The St. Regis in New York. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at An archived replay of the webcast will be available on the Company’s website after the conference.
  • Citi’s 13th Annual Biotech Conference, Thursday, September 6, 2018, in Boston. Dr. Fambrough will be available for one-on-one meetings with investors at the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit

Source: Dicerna Pharmaceuticals, Inc.

Rx Communications Group
Paula Schwartz, 917-322-2216
Alex Van Rees, 973-442-1555 ext. 111